Drug therapy in Behçet's disease.
Behçet's disease is one of the most difficult forms of uveitis to treat. Variety in disease presentation and severity, as well as regional differences in standard of care, demand a tailor-made approach. Anterior segment inflammation generally responds to topical corticosteroids. However, the onset of posterior segment inflammation usually requires the advancement of treatment to periocular injections and/or oral administration of corticosteroids. Cyclosporin, either alone or in combination with corticosteroids, is considered in refractory patients. Other immunosuppressive drugs, such as azathioprine and chlorambucil, may be considered in difficult cases. Finally, preliminary results suggest efficacy with the immunomodulatory agent interferon alfa, although further clinical trials are necessary to evaluate safety and efficacy.
Okada
A A
AA
Kyorin Eye Center, Kyorin University School of Medicine, Tokyo, Japan.
D000818:Animals; D000869:Anterior Eye Segment / Q000187:drug effects / Q000473:pathology; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D012449:Safety; D012720:Severity of Illness Index
D005938:Glucocorticoids; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D016898:Interferon-alpha